

Susan L Slager

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4872426/susan-l-slager-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

417
papers

15,504
citations

65
h-index

116
g-index

432
ext. papers

17,849
ext. citations

4.9
avg, IF

5.57
L-index

#	Paper	IF	Citations
4 ¹⁷	Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?. <i>Blood Cancer Journal</i> , 2022 , 12, 18	7	1
4 ¹⁶	Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.. <i>Blood Cancer Journal</i> , 2022 , 12, 67	7	1
4 ¹⁵	Genome-wide meta-analysis of monoclonal gammopathy of undetermined significance (MGUS) identifies risk loci impacting IRF-6.. <i>Blood Cancer Journal</i> , 2022 , 12, 60	7	
4 ¹⁴	Validation and functional characterization of GWAS-identified variants for chronic lymphocytic leukemia: a CRuCIAL study.. <i>Blood Cancer Journal</i> , 2022 , 12, 79	7	
4 ¹³	Utilization of a Targeted Next Generation Sequencing Assay to Identify Copy Number Alterations in Chronic Lymphocytic Leukemia and Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2021 , 138, 4677-4677	2.2	
4 ¹²	Favorable Modulation of Chimeric Antigen Receptor T Cells Safety and Efficacy By the Non-Covalent BTK Inhibitor Vecabrutinib. <i>Blood</i> , 2021 , 138, 906-906	2.2	0
4 ¹¹	Prevalence and Overall Survival of Low Count Monoclonal B-Cell Lymphocytosis (LC-MBL): A Screening Study of 8,297 Individuals from the Mayo Clinic Biobank. <i>Blood</i> , 2021 , 138, 2632-2632	2.2	0
4 ¹⁰	TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma. <i>Blood</i> , 2021 , 138, 901-901	2.2	0
4 ⁰⁹	Optimized Inhibition of GM-CSF in Preclinical Models of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. <i>Blood</i> , 2021 , 138, 2777-2777	2.2	
4 ⁰⁸	The Impact of Prior Treatment with a CD19 Targeting Monoclonal Antibody on Subsequent Treatment with CD19 Targeting CART Cell Therapy in Preclinical Models. <i>Blood</i> , 2021 , 138, 2412-2412	2.2	0
4 ⁰⁷	Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with the Combination of Ibrutinib (I) and Venetoclax (V; I+V) after Progression on I Alone (V-naïve) or after Progression on Sequential I and V (Double-Refractory). <i>Blood</i> , 2021 , 138, 1560-1560	2.2	
4 ⁰⁶	Relationship and Susceptibility to Serious Infections Among Monoclonal B-Cell Lymphocytosis (MBL), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Clonal Hematopoiesis (CH) Premalignant Conditions. <i>Blood</i> , 2021 , 138, 3739-3739	2.2	
4 ⁰⁵	B Cell Receptor Signaling Drives APOBEC3 Expression Via Direct Enhancer Regulation in Chronic Lymphocytic Leukemia B Cells. <i>Blood</i> , 2021 , 138, 3313-3313	2.2	
4 ⁰⁴	TP53 Aberrations and Outcomes in MBL and Untreated CLL. <i>Blood</i> , 2021 , 138, 2618-2618	2.2	
4 ⁰³	Differential transcriptomic profiling in ibrutinib-naïve versus ibrutinib-resistant Richter syndrome. <i>Hematological Oncology</i> , 2021 ,	1.3	0
4 ⁰²	Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. <i>American Journal of Hematology</i> , 2021 , 97, 90	7.1	4
4 ⁰¹	Aspirin and other nonsteroidal anti-inflammatory drugs, statins and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2021 , 149, 535-545	7.5	0

400	Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. <i>Human Molecular Genetics</i> , 2021 , 30, 1142-1153	5.6	
399	Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. <i>Blood Cancer Journal</i> , 2021 , 11, 47	7	1
398	Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer. <i>International Journal of Epidemiology</i> , 2021 , 50, 1325-1334	7.8	0
397	Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients. <i>International Journal of Cancer</i> , 2021 , 149, 327-336	7.5	1
396	The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. <i>Blood</i> , 2021 , 138, 149-159	2.2	4
395	Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families. <i>Blood</i> , 2021 , 137, 2046-2056	2.2	4
394	Epigenetic alteration contributes to the transcriptional reprogramming in T-cell prolymphocytic leukemia. <i>Scientific Reports</i> , 2021 , 11, 8318	4.9	2
393	The prognostic significance of del6q23 in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2021 , 96, E203-E206	7.1	1
392	Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era. <i>American Journal of Hematology</i> , 2021 , 96, 979-988	7.1	1
391	Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. <i>Blood Cancer Journal</i> , 2021 , 11, 86	7	4
390	Occupational insecticide exposure and risk of non-Hodgkin lymphoma: A pooled case-control study from the InterLymph Consortium. <i>International Journal of Cancer</i> , 2021 , 149, 1768-1786	7.5	0
389	Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. <i>Blood Cancer Journal</i> , 2021 , 11, 130	7	5
388	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. <i>Leukemia</i> , 2021 , 35, 522-533	10.7	9
387	Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL). <i>Leukemia</i> , 2021 , 35, 239-244	10.7	7
386	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. <i>Annals of Hematology</i> , 2021 , 100, 143-155	3	7
385	Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. <i>Blood Cancer Discovery</i> , 2021 , 2, 54-69	7	6
384	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. <i>Journal of Translational Genetics and Genomics</i> , 2021 , 5, 200-217	1.7	
383	Polygenic risk score and risk of monoclonal B-cell lymphocytosis in caucasians and risk of chronic lymphocytic leukemia (CLL) in African Americans. <i>Leukemia</i> , 2021 ,	10.7	1

382	Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. <i>Blood Cancer Journal</i> , 2021 , 11, 140	7	0
381	The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. <i>Cancer Medicine</i> , 2020 , 9, 3390-3399	4.8	19
380	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. <i>Nature Communications</i> , 2020 , 11, 3353	17.4	32
379	Coinherited genetics of multiple myeloma and its precursor, monoclonal gammopathy of undetermined significance. <i>Blood Advances</i> , 2020 , 4, 2789-2797	7.8	8
378	Infectious mononucleosis, immune genotypes, and non-Hodgkin lymphoma (NHL): an InterLymph Consortium study. <i>Cancer Causes and Control</i> , 2020 , 31, 451-462	2.8	2
377	Genome-wide Association Study Identifies HLA-DPB1 as a Significant Risk Factor for Severe Aplastic Anemia. <i>American Journal of Human Genetics</i> , 2020 , 106, 264-271	11	8
376	Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index. <i>American Journal of Hematology</i> , 2020 , 95, 906-917	7.1	6
375	Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes. <i>Blood</i> , 2020 , 136, 35-36	2.2	
374	Comparison of MGUS Prevalence By Race and Family History Risk Groups Using a High Sensitivity Screening Method (MASS-FIX). <i>Blood</i> , 2020 , 136, 40-41	2.2	1
373	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older. <i>Blood</i> , 2020 , 136, 26-27	2.2	
372	Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 10-12	2.2	
371	Axl-RTK Inhibition Modulates Monocyte Immune Response to Enhance the Anti-Tumor Effects of CD19 Redirected Chimeric Antigen Receptor T Cells in Preclinical Models. <i>Blood</i> , 2020 , 136, 28-29	2.2	
370	Vesicular Stomatitis Virus (VSV) Engineered to Express CD19 Stimulates Anti-CD19 Chimeric Antigen Receptor Modified T Cells and Promotes Their Anti-Tumor Effects. <i>Blood</i> , 2020 , 136, 30-31	2.2	1
369	Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 12-13	2.2	
368	Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 1-1	2.2	
367	Body Mass Index and Clinical Factors Associated with Monoclonal Gammopathy of Undetermined Significance (MGUS) Progression in Olmsted County, Minnesota. <i>Blood</i> , 2020 , 136, 15-16	2.2	
366	Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib. <i>Blood</i> , 2020 , 136, 30-31	2.2	1
365	High Dimensional Tissue-Based Spatial Analysis of the Tumor Microenvironment of Follicular Lymphoma Reveals Unique Immune Niches inside Malignant Follicles. <i>Blood</i> , 2020 , 136, 17-18	2.2	

364	Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020 , 136, 16-17	2.2	1
363	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020 , 136, 26-27	2.2	0
362	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. <i>Blood</i> , 2020 , 136, 7-8	2.2	
361	Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 49-50	2.2	1
360	Venetoclax Has Modest Efficacy in the Treatment of Patients with Relapsed T-Cell Prolymphocytic Leukemia. <i>Blood</i> , 2020 , 136, 39-40	2.2	1
359	The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. <i>Haematologica</i> , 2020 , 105, 2675-2678	6.6	11
358	Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2383-2388	1.9	11
357	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1221-1228	11.6	12
356	Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. <i>American Journal of Hematology</i> , 2020 , 95, E57-E60	7.1	5
355	Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. <i>Oncologist</i> , 2020 , 25, 974-980	5.7	5
354	Risk factors for hypogammaglobulinemia in chronic lymphocytic leukemia patients treated with anti-CD20 monoclonal antibody-based therapies. <i>Journal of Hematopathology</i> , 2020 , 13, 221-229	0.4	
353	Delineation of clinical and biological factors associated with cutaneous squamous cell carcinoma among patients with chronic lymphocytic leukemia. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1581-1589	4.5	2
352	Chronic lymphocytic leukemia (CLL) risk is mediated by multiple enhancer variants within CLL risk loci. <i>Human Molecular Genetics</i> , 2020 , 29, 2761-2774	5.6	4
351	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020 , 107, 837-848	11	12
350	Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. <i>EJHaem</i> , 2020 , 1, 537-544	0.9	0
349	Association of germline variation with the survival of women with pathogenic variants and breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 44	7.8	3
348	Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. <i>Haematologica</i> , 2020 , 105, 765-773	6.6	31
347	Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. <i>Human Molecular Genetics</i> , 2020 , 29, 70-79	5.6	12

346	Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1074-1078	4	4
345	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019 , 9, 73	7	19
344	Two truncating variants in FANCC and breast cancer risk. <i>Scientific Reports</i> , 2019 , 9, 12524	4.9	2
343	Comparison of tumor staging systems for cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia. <i>Journal of the American Academy of Dermatology</i> , 2019 , 80, 639-645	4.5	5
342	Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. <i>British Journal of Haematology</i> , 2019 , 186, 820-828	4.5	9
341	Blood transfusion history and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis. <i>Cancer Causes and Control</i> , 2019 , 30, 889-900	2.8	2
340	Recurrent mutations in ALK-negative anaplastic large cell lymphoma. <i>Blood</i> , 2019 , 133, 2776-2789	2.2	23
339	Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2712-2719	1.9	28
338	Host genetic variation in tumor necrosis factor and nuclear factor- κ B pathways and overall survival in mantle cell lymphoma: A discovery and replication study. <i>American Journal of Hematology</i> , 2019 , 94, E153-E155	7.1	1
337	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. <i>American Journal of Hematology</i> , 2019 , 94, 658-666	7.1	9
336	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. <i>Journal of Clinical Oncology</i> , 2019 , 37, 144-152	2.2	80
335	Identification of factors associated with duplicate rate in ChIP-seq data. <i>PLoS ONE</i> , 2019 , 14, e0214723	3.7	2
334	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2019 , 9, 1539	5.3	1
333	Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood Cancer Journal</i> , 2019 , 9, 59	7	2
332	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. <i>Genetic Epidemiology</i> , 2019 , 43, 844-863	2.6	15
331	A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2019 , 134, 4306-4306	2.2	3
330	BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression. <i>Blood</i> , 2019 , 134, 3050-3050	2.2	2
329	Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database. <i>Blood</i> , 2019 , 134, 1610-1610	2.2	2

328	Intrafollicular CD4+ T-Cells As an Independent Predictor of Early Clinical Failure in Newly Diagnosed Follicular Lymphoma. <i>Blood</i> , 2019 , 134, 121-121	2.2	7
327	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019 , 134, 69-69	2.2	3
326	Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis. <i>Blood</i> , 2019 , 134, 3022-3022	2.2	
325	Association between a Polygenic Risk Score for Multiple Myeloma Risk and Overall Survival. <i>Blood</i> , 2019 , 134, 4366-4366	2.2	
324	Genetic Risk Factors for Cardiovascular Disease in Adult Lymphoma Patients. <i>Blood</i> , 2019 , 134, 5215-5215	2.2	
323	Genomic Landscape Including Novel Mutational Drivers in Relapsed/Refractory Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019 , 134, 919-919	2.2	
322	Clustering of Transcriptomic Signatures in Newly Diagnosed Diffuse Large B-Cell Lymphoma Identifies Two High-Risk Subgroups Which Increase in Prevalence at Relapse. <i>Blood</i> , 2019 , 134, 923-923	2.2	
321	Germline Variation Predicts Treatment Response in Multiple Myeloma. <i>Blood</i> , 2019 , 134, 4397-4397	2.2	
320	Genomic Analysis of R2CHOP-Treated DLBCL Reveals a High-Risk Population Driven By Inflammatory Pathways. <i>Blood</i> , 2019 , 134, 1480-1480	2.2	
319	Prevalence and the Impact of Hypogammaglobulinemia in Newly Diagnosed, Untreated Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2019 , 134, 1604-1604	2.2	1
318	Treatment and Lifestyle Risk Factors for Cardiovascular Disease Post Lymphoma Diagnosis: A Prospective Study in the Modern Treatment Era. <i>Blood</i> , 2019 , 134, 422-422	2.2	
317	Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL). <i>Blood</i> , 2019 , 134, 852-852	2.2	
316	The Role of Imaging in Predicting Time to First Treatment and Overall Survival in Individuals with CLL-like High Count Monoclonal B-Cell Lymphocytosis. <i>Blood</i> , 2019 , 134, 3037-3037	2.2	
315	Genome-Wide Association Study Identifies an Immune-Related Etiology for Severe Aplastic Anemia. <i>Blood</i> , 2019 , 134, 1224-1224	2.2	
314	CORR ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor- γ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation. <i>Clinical Orthopaedics and Related Research</i> , 2019 , 477, 1800-1812	2.2	7
313	Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy. <i>Clinical Epidemiology</i> , 2019 , 11, 987-996	5.9	3
312	Risk of MGUS in relatives of multiple myeloma cases by clinical and tumor characteristics. <i>Leukemia</i> , 2019 , 33, 499-507	10.7	4
311	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019 , 104, 21-34	11	363

310	IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes. <i>American Journal of Hematology</i> , 2019 , 94, 338-345	7.1	11
309	Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. <i>Haematologica</i> , 2018 , 103, e237-e240	6.6	9
308	Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. <i>Blood</i> , 2018 , 131, 2541-2551	2.2	15
307	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018 , 132, 49-58	2.2	90
306	Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma. <i>Cancer Research</i> , 2018 , 78, 2747-2759	10.1	32
305	A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia. <i>Human Molecular Genetics</i> , 2018 , 27, 1809-1818	5.6	3
304	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018 , 180, 286-290	4.5	11
303	Comparative analysis of de novo assemblers for variation discovery in personal genomes. <i>Briefings in Bioinformatics</i> , 2018 , 19, 893-904	13.4	5
302	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018 , 8, 73	7	19
301	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. <i>Cancer Research</i> , 2018 , 78, 4086-4096	10.1	18
300	Genetics in Lymphomagenesis 2018 , 723-753		
299	Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre. <i>British Journal of Haematology</i> , 2018 , 183, 421-427	4.5	25
298	The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Reflects the Demographics and Subtypes of Patients Diagnosed with Non-Hodgkin Lymphoma in the United States. <i>Blood</i> , 2018 , 132, 1702-1702	2.2	3
297	Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL. <i>Blood</i> , 2018 , 132, 4204-4204	2.2	1
296	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. <i>PLoS Genetics</i> , 2018 , 14, e1007111	6	20
295	Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL). <i>Blood</i> , 2018 , 132, 3116-3116	2.2	
294	Clinical Characteristics and Outcomes of Chronic Lymphocytic Leukemia Patients with Richter Transformation. <i>Blood</i> , 2018 , 132, 1857-1857	2.2	
293	Large-Scale Linkage Analysis of Multiple Myeloma (MM) and Monoclonal Gammopathy of Undetermined Significance (MGUS) Families. <i>Blood</i> , 2018 , 132, 4501-4501	2.2	

292	Clinical and Quality of Life Predictors of Failure to Achieve Event Free Survival at 24 Months in Patients Aged 70 Years and Older with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2018 , 132, 3579-3579	2.2	
291	Association between the Risk of Low/High-Count Monoclonal B-Cell Lymphocytosis (MBL) and the Chronic Lymphocytic Leukemia (CLL) Polygenic Risk Score (PRS). <i>Blood</i> , 2018 , 132, 5538-5538	2.2	
290	Patterns of Care and Outcomes in Mantle Cell Lymphoma in the Modern Immunochemotherapy Era. <i>Blood</i> , 2018 , 132, 4140-4140	2.2	
289	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. <i>Haematologica</i> , 2018 , 103, 297-303	6.6	14
288	Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy. <i>Oncotarget</i> , 2018 , 9, 37173-37184	3.3	7
287	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1603-1610	2.2	63
286	Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2018 , 8, 97	7	16
285	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. <i>Nature Communications</i> , 2018 , 9, 4182	17.4	8
284	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018 , 93, 1543-1550	7.1	8
283	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018 , 182, 644-653	4.5	15
282	FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017 , 35, 447-455	1.3	6
281	Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. <i>Cancer Research</i> , 2017 , 77, 2789-2799	10.1	49
280	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017 , 8, 14175	17.4	54
279	Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2017 , 102, e22-e25	6.6	8
278	CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2017 , 178, 99-105	4.5	15
277	Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. <i>British Journal of Haematology</i> , 2017 , 178, 394-402	4.5	37
276	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017 , 46, 1753-1754	7.8	35
275	Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings. <i>American Journal of Hematology</i> , 2017 , 92, 1362-1369	7.1	8

274	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017 , 4, e000187	4.6	10
273	Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1376-1383	1.9	30
272	Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia and Lymphoma</i> , 2017 , 58, 1630-1639	1.9	71
271	Prevalence of Low Count (LC) Monoclonal B Cell Lymphocytosis (MBL) and Serious Infections in a Population-Based Cohort of U.S. Adults Participating in a Large Bio-Repository. <i>Blood</i> , 2017 , 130, 831-831 ²	1.2	3
270	The Level of Physical Activity before and after Lymphoma Diagnosis Impacts Overall and Lymphoma-Specific Survival. <i>Blood</i> , 2017 , 130, 914-914	2.2	1
269	Cytomegalovirus infection does not impact on survival or time to first treatment in patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016 , 91, 776-81	7.1	11
268	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. <i>Nature Communications</i> , 2016 , 7, 11375	17.4	64
267	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. <i>Nature Communications</i> , 2016 , 7, 12675	17.4	53
266	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016 , 7, 10933	17.4	70
265	Analysis of racial variations in disease characteristics, treatment patterns, and outcomes of patients with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2016 , 91, 677-80	7.1	9
264	ChIP-seq in studying epigenetic mechanisms of disease and promoting precision medicine: progresses and future directions. <i>Epigenomics</i> , 2016 , 8, 1239-58	4.4	16
263	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016 , 25, 1663-76	5.6	39
262	Genome-Wide Epigenetic Studies in Human Disease: A Primer on -Omic Technologies. <i>American Journal of Epidemiology</i> , 2016 , 183, 96-109	3.8	18
261	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016 , 128, 1104-1104	2.2	1
260	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016 , 128, 3034-3034	2.2	4
259	Role of Lncrnas in Early Stage Immunoglobulin Heavy Chain Variable Region (IGHV) Unmutated CLL Disease Progression. <i>Blood</i> , 2016 , 128, 4364-4364	2.2	1
258	Skin Cancers Among Chronic Lymphocytic Leukemia (CLL) Patients - the Effect of UV Radiation and CLL Clinical Characteristics. <i>Blood</i> , 2016 , 128, 4772-4772	2.2	4
257	Risk of Monoclonal Gammopathy of Undetermined Significance in First-Degree Relatives of Multiple Myeloma Cases By Cytogenetic Subtype. <i>Blood</i> , 2016 , 128, 4425-4425	2.2	

256	Sensitivity of Ibrutinib Exposed Chronic Lymphocytic Leukemia B-Cells to Inhibition of Axl Receptor Tyrosine Kinase. <i>Blood</i> , 2016 , 128, 2020-2020	2.2	
255	Liver Dysfunction in Previously Untreated Chronic Lymphocytic Leukemia: Prevalence and Outcomes in a Large Cohort. <i>Blood</i> , 2016 , 128, 5585-5585	2.2	
254	The Role of Splenectomy in the Care and Treatment of the CLL Patient. <i>Blood</i> , 2016 , 128, 5575-5575	2.2	
253	No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era. <i>Blood</i> , 2016 , 128, 107-107	2.2	
252	Clinically Ascertained Monoclonal B-Cell Lymphocytosis: Risk of Progression to Chronic Lymphocytic Leukemia Requiring Therapy and Outcomes. <i>Blood</i> , 2016 , 128, 3228-3228	2.2	
251	Whole-Exome Analysis Reveals Novel Somatic Genomic Alterations Associated with Cell of Origin in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 2935-2935	2.2	
250	Liver Biopsy in Patients with Chronic Lymphocytic Leukemia: Indications and Pathological Findings. <i>Blood</i> , 2016 , 128, 5592-5592	2.2	1
249	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. <i>PLoS ONE</i> , 2016 , 11, e0160316	3.7	11
248	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016 , 91, 179-84	7.1	30
247	Relationship of blood monocytes with chronic lymphocytic leukemia aggressiveness and outcomes: a multi-institutional study. <i>American Journal of Hematology</i> , 2016 , 91, 687-91	7.1	11
246	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016 , 53, 800-811	5.8	121
245	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. <i>Breast Cancer Research</i> , 2016 , 18, 64	8.3	25
244	A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1609-1618	4	13
243	An analytical workflow for accurate variant discovery in highly divergent regions. <i>BMC Genomics</i> , 2016 , 17, 703	4.5	12
242	Impact of post-alignment processing in variant discovery from whole exome data. <i>BMC Bioinformatics</i> , 2016 , 17, 403	3.6	19
241	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. <i>American Journal of Human Genetics</i> , 2016 , 99, 903-911	11	43
240	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016 , 91, 1096-1101	7.1	137
239	Associations of non-Hodgkin Lymphoma (NHL) risk with autoimmune conditions according to putative NHL loci. <i>American Journal of Epidemiology</i> , 2015 , 181, 406-21	3.8	42

238	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. <i>Nature Genetics</i> , 2015 , 47, 373-80	36.3	406
237	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. <i>Nature Communications</i> , 2015 , 6, 7539	17.4	31
236	Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. <i>Journal of Oncology Practice</i> , 2015 , 11, 252-8	3.1	77
235	Base resolution methylome profiling: considerations in platform selection, data preprocessing and analysis. <i>Epigenomics</i> , 2015 , 7, 813-28	4.4	65
234	Identification of recurrent truncated DDX3X mutations in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015 , 169, 445-8	4.5	31
233	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3930-7	2.2	19
232	Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication. <i>Leukemia and Lymphoma</i> , 2015 , 56, 311-4	1.9	12
231	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. <i>Human Molecular Genetics</i> , 2015 , 24, 285-98	5.6	35
230	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- κ B positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , 2015 , 125, 3118-27	2.2	47
229	BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. <i>Blood</i> , 2015 , 125, 658-67	2.2	79
228	Deep sequencing identifies genetic heterogeneity and recurrent convergent evolution in chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 125, 492-8	2.2	44
227	Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. <i>Blood</i> , 2015 , 125, 992-8	2.2	36
226	The efficacy of ibrutinib in the treatment of Richter syndrome. <i>Blood</i> , 2015 , 125, 1676-8	2.2	57
225	Familial predisposition and genetic risk factors for lymphoma. <i>Blood</i> , 2015 , 126, 2265-73	2.2	91
224	Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes. <i>Cancer</i> , 2015 , 121, 2883-91	6.4	47
223	Tumor Budding in Colorectal Carcinoma: Confirmation of Prognostic Significance and Histologic Cutoff in a Population-based Cohort. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 1340-6	6.7	72
222	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015 , 6, 5751	17.4	44
221	Non-Hodgkin Lymphoma, Body Mass Index, and Cytokine Polymorphisms: A Pooled Analysis from the InterLymph Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1061-70	4	5

220	Associations between Environmental Exposures and Incident Colorectal Cancer by ESR2 Protein Expression Level in a Population-Based Cohort of Older Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 713-9	4	8
219	Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2015 , 90, 334-8	7.1	56
218	Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 304-11	11	435
217	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. <i>Human Molecular Genetics</i> , 2015 , 24, 2966-84	5.6	36
216	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015 , 96, 5-20	11	59
215	Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL): An Analysis of a Large Cohort of Patients Treated in Routine Clinical Practice. <i>Blood</i> , 2015 , 126, 2935-2935	2.2	15
214	Atrial Fibrillation in Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015 , 126, 2950-2950	2.2	5
213	Pure Red Cell Aplasia (PRCA) in Chronic Lymphocytic Leukemia (CLL): Etiology, Therapy, and Outcomes. <i>Blood</i> , 2015 , 126, 4169-4169	2.2	3
212	Disease Progression and Complications Are the Main Cause of Death in Patients with Chronic Lymphocytic Leukemia (CLL) Independent of Age and Comorbidities at Diagnosis. <i>Blood</i> , 2015 , 126, 5265-5265	2.2	4
211	The Importance of Pharmacovigilance during Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in Routine Clinical Practice. <i>Blood</i> , 2015 , 126, 717-717	2.2	7
210	Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015 , 126, 131-131	2.2	
209	Correlation Between Peripheral Blood Counts and Extent of Bone Marrow Infiltration in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015 , 126, 2926-2926	2.2	
208	Event-Free Survival at 12 Months and Subsequent Overall Survival in Patients with Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015 , 126, 1501-1501	2.2	
207	Mutations in Driver Genes and Changes in Clonal Dynamics Are Associated with Shorter Time to Treatment in MBL Cases. <i>Blood</i> , 2015 , 126, 5264-5264	2.2	
206	Associations between cigarette smoking, hormone therapy, and folate intake with incident colorectal cancer by TP53 protein expression level in a population-based cohort of older women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 350-5	4	11
205	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. <i>Carcinogenesis</i> , 2014 , 35, 1012-9	4.6	121
204	Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014 , 89, 639-45	7.1	20
203	Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 130-44	4.8	199

202	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014 , 46, 1233-8	36.3	108
201	Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 106-14	4.8	24
200	Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. <i>American Journal of Human Genetics</i> , 2014 , 95, 462-71	11	74
199	Medical history, lifestyle, family history, and occupational risk factors for chronic lymphocytic leukemia/small lymphocytic lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 41-51	4.8	66
198	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. <i>Nature Communications</i> , 2014 , 4, 4999	17.4	87
197	PatternCNV: a versatile tool for detecting copy number changes from exome sequencing data. <i>Bioinformatics</i> , 2014 , 30, 2678-80	7.2	35
196	Incidence of chronic lymphocytic leukemia and high-count monoclonal B-cell lymphocytosis using the 2008 guidelines. <i>Cancer</i> , 2014 , 120, 2000-5	6.4	27
195	Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 76-86	4.8	27
194	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. <i>Human Molecular Genetics</i> , 2014 , 23, 6034-46	5.6	11
193	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. <i>Breast Cancer Research</i> , 2014 , 16, R51	8.3	12
192	MicroRNA related polymorphisms and breast cancer risk. <i>PLoS ONE</i> , 2014 , 9, e109973	3.7	37
191	Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 15-25	4.8	73
190	Rationale and Design of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 1-14	4.8	39
189	Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia. <i>Journal of Oncology Practice</i> , 2014 , 10, e1-4	3.1	14
188	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. <i>PLoS Genetics</i> , 2014 , 10, e1004256	6	33
187	Medical history, lifestyle, and occupational risk factors for hairy cell leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 115-24	4.8	26
186	Chronic lymphocytic leukemia in young (≥ 5 years) patients: a comprehensive analysis of prognostic factors and outcomes. <i>Haematologica</i> , 2014 , 99, 140-7	6.6	47
185	Genetic risk of chronic lymphocytic leukemia: a tale of two cities. <i>Leukemia and Lymphoma</i> , 2014 , 55, 735-6	1.9	1

184	Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2079-84 ¹⁻⁹	34
183	Medical history, lifestyle, family history, and occupational risk factors for adult acute lymphocytic leukemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 125-9	4.8 14
182	RVboost: RNA-seq variants prioritization using a boosting method. <i>Bioinformatics</i> , 2014 , 30, 3414-6	7.2 21
181	Medical history, lifestyle, family history, and occupational risk factors for marginal zone lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 52-65	4.8 55
180	Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. <i>Journal of the National Cancer Institute Monographs</i> , 2014 , 2014, 87-97	4.8 28
179	Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2014 , 124, 1664-1664	2.2 7
178	Quality of Life at Diagnosis Independently Predicts Survival in Patients with Aggressive Lymphoma. <i>Blood</i> , 2014 , 124, 205-205	2.2 2
177	Racial Variations in Disease Characteristics, Presentations, Treatments, and Outcomes in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014 , 124, 1989-1989	2.2
176	Exome Sequencing in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM) Families Identifies Cosegregating Functional Variants. <i>Blood</i> , 2014 , 124, 1967-1967	2.2
175	Validation of Elevated Blood Soluble PD-L1 As an Independent Prognostic Marker in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2014 , 124, 2998-2998	2.2 1
174	Transfusion History and Risk of Non-Hodgkin Lymphoma (NHL): an Interlymph Pooled Analysis. <i>Blood</i> , 2014 , 124, 3039-3039	2.2
173	Genomic Diversity of Newly Diagnosed Follicular Lymphoma: a Pilot Investigation. <i>Blood</i> , 2014 , 124, 1691-1691	2.2
172	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2013 , 62, 1475-84	7.4 26
171	Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3272-8	2.2 206
170	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013 , 93, 1046-60	11 80
169	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013 , 45, 371-84, 384e1-2	36.3 422
168	Genetic susceptibility to chronic lymphocytic leukemia. <i>Seminars in Hematology</i> , 2013 , 50, 296-302	4 23
167	Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. <i>British Journal of Haematology</i> , 2013 , 163, 326-33	4.5 31

166	Smoking, variation in N-acetyltransferase 1 (NAT1) and 2 (NAT2), and risk of non-Hodgkin lymphoma: a pooled analysis within the InterLymph consortium. <i>Cancer Causes and Control</i> , 2013 , 24, 125-34	2.8	16
165	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: results from two independent cohorts. <i>Cytokine</i> , 2013 , 64, 523-31	4	15
164	Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. <i>Journal of Clinical Oncology</i> , 2013 , 31, 930-7	2.2	43
163	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013 , 45, 392-8, 398e1-2	36.3	327
162	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013 , 45, 353-61, 361e1-2	36.3	813
161	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2013 , 45, 868-76	36.3	147
160	FCGR2A and FCGR3A polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2571-3	1.9	7
159	The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013 , 54, 290-7	1.9	36
158	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003212	6	209
157	Mapping of the IRF8 gene identifies a 3'UTR variant associated with risk of chronic lymphocytic leukemia but not other common non-Hodgkin lymphoma subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 461-6	4	11
156	Prognostic significance of pretreatment serum cytokines in classical Hodgkin lymphoma. <i>Clinical Cancer Research</i> , 2013 , 19, 6812-9	12.9	58
155	Trans fatty acid intake is associated with increased risk and n3 fatty acid intake with reduced risk of non-hodgkin lymphoma. <i>Journal of Nutrition</i> , 2013 , 143, 672-81	4.1	32
154	Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. <i>British Journal of Haematology</i> , 2013 , 162, 774-82	4.5	151
153	Genetic evidence of PTPN22 effects on chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 237-8	2.2	10
152	Hodgkin Transformation Of Chronic Lymphocytic Leukemia (CLL): Mayo Clinic Experience. <i>Blood</i> , 2013 , 122, 1642-1642	2.2	5
151	Heritable Predisposition To Richter Syndrome In Patients With Chronic Lymphocytic Leukemia. <i>Blood</i> , 2013 , 122, 2867-2867	2.2	3
150	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. <i>Blood</i> , 2013 , 122, 362-362	2.2	2
149	Hypogammaglobulinemia In Patients With Previously Untreated Chronic Lymphocytic Leukemia: Clinical Correlates and Outcomes. <i>Blood</i> , 2013 , 122, 4178-4178	2.2	2

148	Outcomes Of Chronic Lymphocytic Leukemia Patients With Richter Syndrome. <i>Blood</i> , 2013 , 122, 4179-4179		4
147	Whole-Exome Analysis Of DLBCL Tumors Reveals a Unique Genetic Signature Associated With Aggressive Disease. <i>Blood</i> , 2013 , 122, 499-499	2.2	1
146	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013 , 122, 76-76	2.2	1
145	Genomic Landscape and Clonal Heterogeneity Underlying Progression and Relapse In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2013 , 122, 2855-2855	2.2	
144	Comparison Of Single Nucleotide Mutations (SNVs) and Copy Number Variants (CNVs) Detection In Formalin Fixed Paraffin Embedded (FFPE) and Paired Frozen Tumor Tissues Using Target Capture and Sequencing Approach. <i>Blood</i> , 2013 , 122, 1784-1784	2.2	
143	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. <i>Blood</i> , 2013 , 122, 626-626	2.2	
142	Increased prevalence of light chain monoclonal gammopathy of undetermined significance (LC-MGUS) in first-degree relatives of individuals with multiple myeloma. <i>British Journal of Haematology</i> , 2012 , 157, 472-5	4.5	7
141	PRRC2A and BCL2L11 gene variants influence risk of non-Hodgkin lymphoma: results from the InterLymph consortium. <i>Blood</i> , 2012 , 120, 4645-8	2.2	23
140	A two-stage evaluation of genetic variation in immune and inflammation genes with risk of non-Hodgkin lymphoma identifies new susceptibility locus in 6p21.3 region. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1799-806	4	22
139	Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia. <i>Blood</i> , 2012 , 120, 843-6	2.2	63
138	A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. <i>Blood</i> , 2012 , 119, 469-75	2.2	52
137	Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes. <i>British Journal of Haematology</i> , 2012 , 159, 572-6	4.5	12
136	Postmenopausal hormone therapy and colorectal cancer risk in relation to somatic KRAS mutation status among older women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 681-4	4	23
135	Cigarette smoking and colorectal cancer risk by KRAS mutation status among older women. <i>American Journal of Gastroenterology</i> , 2012 , 107, 782-9	0.7	28
134	Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. <i>Gut</i> , 2012 , 61, 1299-305	19.2	34
133	The association between early life and adult body mass index and physical activity with risk of non-Hodgkin lymphoma: impact of gender. <i>Annals of Epidemiology</i> , 2012 , 22, 855-62	6.4	15
132	Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study. <i>Cytokine</i> , 2012 , 60, 882-9	4	46
131	A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. <i>Human Molecular Genetics</i> , 2012 , 21, 5373-84	5.6	143

130	A comprehensive study of polymorphisms in the ABCB1, ABCC2, ABCG2, NR112 genes and lymphoma risk. <i>International Journal of Cancer</i> , 2012 , 131, 803-12	7.5	31
129	Food-frequency questionnaire-based estimates of total antioxidant capacity and risk of non-Hodgkin lymphoma. <i>International Journal of Cancer</i> , 2012 , 131, 1158-68	7.5	32
128	Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. <i>American Journal of Hematology</i> , 2012 , 87, 865-9	7.1	31
127	Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2012 , 87, 880-5	7.1	32
126	Hematologist/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). <i>Cancer</i> , 2012 , 118, 1827-37	6.4	30
125	Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma. <i>Cancer Causes and Control</i> , 2012 , 23, 1017-29	2.8	29
124	Associations between intake of folate and related micronutrients with molecularly defined colorectal cancer risks in the Iowa Women's Health Study. <i>Nutrition and Cancer</i> , 2012 , 64, 899-910	2.8	27
123	19p13.1 is a triple-negative-specific breast cancer susceptibility locus. <i>Cancer Research</i> , 2012 , 72, 1795-803	3.1	93
122	Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. <i>Blood</i> , 2012 , 120, 1687-90	2.2	13
121	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 3879-84	11.5	735
120	LIM domain only 2 protein expression, LMO2 germline genetic variation, and overall survival in diffuse large B-cell lymphoma in the pre-rituximab era. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1105-12	1.9	4
119	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. <i>Blood</i> , 2012 , 120, 1540-1540	2.2	1
118	Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource. <i>Blood</i> , 2012 , 120, 1546-1546	2.2	1
117	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (−) Counterparts: Results From University of Iowa/Mayo Clinic SPORE. <i>Blood</i> , 2012 , 120, 1604-1604	2.2	1
116	Very High Risk CLL Characterized by a Double Hit Clone with Both 11q22 and 17p13 Deletion.. <i>Blood</i> , 2012 , 120, 2486-2486	2.2	
115	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012 , 120, 684-684	2.2	
114	Risk of Cancer in Patients with Clinical Monoclonal B-Cell Lymphocytosis (MBL): A Cohort Study of Newly Diagnosed Patients Compared to Controls.. <i>Blood</i> , 2012 , 120, 2893-2893	2.2	
113	Clinical Utility of PET/CT Scanning in Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2012 , 120, 3903-3903		

112	Chronic Lymphocytic Leukemia in Young (≤5 years) Patients: A Comprehensive Analysis of Prognostic Factors and Outcomes.. <i>Blood</i> , 2012 , 120, 2901-2901	2.2	
111	Transformation of Chronic Lymphocytic Leukemia Into Diffuse Large B-Cell Lymphoma (Richter's Syndrome): Large Retrospective Analysis From a Single Institution.. <i>Blood</i> , 2012 , 120, 2902-2902	2.2	
110	Analysis of Stem Cell Transplant Referral in a Cohort of Newly Diagnosed Chronic Lymphocytic Leukemia Patients. <i>Blood</i> , 2012 , 120, 4252-4252	2.2	
109	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012 , 120, 149-149	2.2	
108	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012 , 120, 1563-1563	2.2	
107	Host Genetics and Risk of Cardiovascular Disease in a Prospective Cohort of Adult Non-Hodgkin Lymphoma Survivors. <i>Blood</i> , 2012 , 120, 1573-1573	2.2	
106	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. <i>Blood</i> , 2012 , 120, 3637-3637	2.2	
105	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. <i>Blood</i> , 2012 , 120, 2702-2702	2.2	
104	Alcohol intake and colorectal cancer risk by molecularly defined subtypes in a prospective study of older women. <i>Cancer Prevention Research</i> , 2011 , 4, 2035-43	3.2	16
103	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 117, 1492-8	2.2	100
102	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. <i>Blood</i> , 2011 , 117, 1911-6	2.2	102
101	When the negative is positive. <i>Blood</i> , 2011 , 117, 1441-2	2.2	2
100	Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement. <i>BJU International</i> , 2011 , 108, 1610-5	5.6	5
99	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. <i>Nature Genetics</i> , 2011 , 43, 1210-4	36.3	253
98	Common breast cancer susceptibility loci are associated with triple-negative breast cancer. <i>Cancer Research</i> , 2011 , 71, 6240-9	10.1	100
97	Evaluating the influence of quality control decisions and software algorithms on SNP calling for the affymetrix 6.0 SNP array platform. <i>Human Heredity</i> , 2011 , 71, 221-33	1.1	4
96	GWAS of follicular lymphoma reveals allelic heterogeneity at 6p21.32 and suggests shared genetic susceptibility with diffuse large B-cell lymphoma. <i>PLoS Genetics</i> , 2011 , 7, e1001378	6	84
95	Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011 , 2, 95-113	0.9	35

94	Infectious Complications Among Individuals with Monoclonal B-Cell Lymphocytosis (MBL): A Prospective Case-Control Study of Newly Diagnosed Patients,. <i>Blood</i> , 2011 , 118, 3903-3903	2.2	
93	Pretreatment Serum Cytokines Predict Early Disease Relapse and A Poor Prognosis In Newly Diagnosed Classical Hodgkin Lymphoma (cHL) Patients. <i>Blood</i> , 2011 , 118, 429-429	2.2	
92	Prevalence of MBL Increases Over Time In Relatives of CLL Families,. <i>Blood</i> , 2011 , 118, 3881-3881	2.2	
91	Alemtuzumab Use and Survival After Reduced Intensity Allogeneic Stem Cell Transplantation in High-Risk Chronic Lymphocytic Leukemia (CLL),. <i>Blood</i> , 2011 , 118, 4152-4152	2.2	
90	The Prevalence of Serious Infectious Complications in a Cohort of Non-Referred Patients with Newly Diagnosed Chronic Lymphocytic Leukemia (CLL) Compared to Controls: Results of a Cohort Study. <i>Blood</i> , 2011 , 118, 4610-4610	2.2	
89	Race As a Determinant of Disease Biology and Outcomes in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2011 , 118, 1785-1785	2.2	
88	A comprehensive evaluation of the prognostic significance of 13q deletions in patients with B-chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2010 , 148, 544-50	4.5	66
87	Common occurrence of monoclonal B-cell lymphocytosis among members of high-risk CLL families. <i>British Journal of Haematology</i> , 2010 , 151, 152-8	4.5	50
86	Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. <i>Nature Genetics</i> , 2010 , 42, 661-4	36.3	137
85	Genetic susceptibility variants for chronic lymphocytic leukemia. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1098-102	4	29
84	A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling. <i>Journal of Experimental Medicine</i> , 2010 , 207, 2569-79	16.6	73
83	Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era. <i>Journal of Clinical Oncology</i> , 2010 , 28, 412-7	2.2	65
82	Germline variation in apoptosis pathway genes and risk of non-Hodgkin's lymphoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2847-58	4	32
81	Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. <i>American Journal of Epidemiology</i> , 2010 , 171, 267-76	3.8	121
80	Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4191-8	2.2	164
79	Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. <i>American Journal of Psychiatry</i> , 2010 , 167, 565-73	11.9	52
78	A genomewide association study of citalopram response in major depressive disorder. <i>Biological Psychiatry</i> , 2010 , 67, 133-8	7.9	251
77	Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1233-40	1.9	15

76	Treatment of autoimmune cytopenia complicating progressive chronic lymphocytic leukemia/small lymphocytic lymphoma with rituximab, cyclophosphamide, vincristine, and prednisone. <i>Leukemia and Lymphoma</i> , 2010 , 51, 620-7	1.9	47
75	Familial chronic lymphocytic leukemia. <i>Current Opinion in Hematology</i> , 2010 , 17, 350-5	3.3	28
74	Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2010 , 116, 4777-87	6.4	91
73	Genetic Polymorphisms In Genes Involved In R-CHOP Metabolism and Event-Free and Overall Survival In Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2010 , 116, 996-996	2.2	2
72	Pretreatment Serum Cytokines Predict Early Disease Relapse and a Poor Prognosis In Diffuse Large B-Cell Lymphoma (DLBCL) Patients. <i>Blood</i> , 2010 , 116, 991-991	2.2	
71	Monoclonal and Polyclonal Serum Free Light Chains and Clinical Outcome In Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010 , 116, 2409-2409	2.2	
70	Survival of Patients with Clinically Identified Monoclonal B-Cell Lymphocytosis (MBL) Relative to the Age and Sex Matched General Population. <i>Blood</i> , 2010 , 116, 700-700	2.2	
69	Expression of Interferon Regulatory Factor-4 (IRF4/MUM1) Is Associated with Inferior Overall Survival In Peripheral T-Cell Lymphoma. <i>Blood</i> , 2010 , 116, 140-140	2.2	
68	A BAFF-R Mutation Associated with Non-Hodgkin Lymphoma Exhibits Altered TRAF Binding and Reveals New Insights Into Proximal BAFF-R Signaling. <i>Blood</i> , 2010 , 116, 468-468	2.2	
67	Investigation of CLL-Susceptibility Loci with Monoclonal B-Cell Lymphocytosis (MBL) Risk and Confirmation of Recently Reported CLL-Susceptibility Loci. <i>Blood</i> , 2010 , 116, 2443-2443	2.2	
66	Germline Variation in TNF and NF-Kappa B Pathways and Prognosis In Mantle Cell Lymphoma. <i>Blood</i> , 2010 , 116, 4127-4127	2.2	
65	Infectious Complications In a Prospective Cohort of Community Based Newly Diagnosed Patients with Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2010 , 116, 4610-4610	2.2	
64	Functional and clinical significance of variants localized to 8q24 in colon cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2492-500	4	36
63	Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3959-63	2.2	109
62	Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. <i>Cancer Research</i> , 2009 , 69, 4217-24	10.1	48
61	Validation of a new prognostic index for patients with chronic lymphocytic leukemia. <i>Cancer</i> , 2009 , 115, 363-72	6.4	64
60	Risk of non-Hodgkin lymphoma in association with germline variation in complement genes. <i>British Journal of Haematology</i> , 2009 , 145, 614-23	4.5	14
59	The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2009 , 33, 263-70	2.7	31

58	Familial chronic lymphocytic leukemia: what does it mean to me?. <i>Clinical Lymphoma and Myeloma</i> , 2009 , 9 Suppl 3, S194-7		8
57	Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1261-8	1.9	60
56	B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. <i>Blood</i> , 2009 , 113, 4188-96	2.2	91
55	Monoclonal B-Cell Lymphocytosis Is Commonly Observed Among Unaffected Members of High Risk CLL Families.. <i>Blood</i> , 2009 , 114, 1232-1232	2.2	2
54	Influence of Age at Diagnosis On Utility of Prognostic Testing in Patients with CLL.. <i>Blood</i> , 2009 , 114, 2342-2342	2.2	
53	Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2009 , 114, 1952-1952	2.2	
52	Germline Variation in Apoptosis Pathway Genes and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2009 , 114, 3933-3933	2.2	1
51	Melanoma and Non-Melanoma Skin Cancer in Patients with Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2009 , 114, 1268-1268	2.2	
50	Family-Associated Monoclonal B Lymphocytosis Shows Differences From CLL That Suggest An Indolent Biology.. <i>Blood</i> , 2009 , 114, 1241-1241	2.2	
49	Treatment of Patients with Autoimmune Cytopenia and Progressive CLL Using Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP).. <i>Blood</i> , 2009 , 114, 4410-4410	2.2	
48	Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.. <i>Blood</i> , 2009 , 114, 440-440	2.2	
47	The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. <i>British Journal of Haematology</i> , 2008 , 141, 615-21	4.5	84
46	Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 49-56	1.9	146
45	Non-Hodgkin lymphoma and obesity: a pooled analysis from the InterLymph Consortium. <i>International Journal of Cancer</i> , 2008 , 122, 2062-70	7.5	88
44	CD5+ Chronic B-Cell Lymphoproliferative Disorders Could Contain a Novel Disease Entity.. <i>Blood</i> , 2008 , 112, 2065-2065	2.2	1
43	Family-Associated Monoclonal B Lymphocytosis Is Commonly Oligoclonal and Expresses Markers Associated with Adverse Risk in CLL. <i>Blood</i> , 2008 , 112, 3144-3144	2.2	2
42	Genetic Variation in Genes That Regulate T-Cell Differentiation and Function Is Associated with An Increased Risk of Developing B-Cell Non- Hodgkin Lymphoma. <i>Blood</i> , 2008 , 112, 3762-3762	2.2	2
41	Statin Use and Prognosis in Patients with Follicular Lymphoma (FL) and Diffuse Large B Cell Lymphoma (DLBCL). <i>Blood</i> , 2008 , 112, 583-583	2.2	1

40	Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. <i>PLoS ONE</i> , 2008 , 3, e1872	3.7	129
39	Treatment Free Survival of Patients with MBL and Early CLL: Follow-up of 405 Patients at Mayo Clinic.. <i>Blood</i> , 2008 , 112, 2063-2063	2.2	
38	B-Cell Count and Survival: Differentiating Chronic Lymphocytic Leukemia (CLL) from and Monoclonal B-Cell Lymphocytosis (MBL) Based on Clinical Outcome.. <i>Blood</i> , 2008 , 112, 2062-2062	2.2	
37	Higher Intakes of Vegetables, Vitamin E, Manganese and Zinc Are Associated with a Lower Risk of Non-Hodgkin Lymphoma (NHL): Results from a Case-Control Study. <i>Blood</i> , 2008 , 112, 3771-3771	2.2	
36	Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. <i>Biological Psychiatry</i> , 2007 , 61, 734-42	7.9	133
35	Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. <i>British Journal of Haematology</i> , 2007 , 139, 255-64	4.5	90
34	Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007 , 139, 398-404	4.5	68
33	Chronic lymphocytic leukaemia genetics overview. <i>British Journal of Haematology</i> , 2007 , 139, 630-4	4.5	22
32	Susceptibility genes and B-chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007 , 139, 762-71	4.5	23
31	Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). <i>Blood</i> , 2007 , 109, 3479-88	2.2	145
30	Genetic variation in 1253 immune and inflammation genes and risk of non-Hodgkin lymphoma. <i>Blood</i> , 2007 , 110, 4455-63	2.2	127
29	A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. <i>Blood</i> , 2007 , 110, 3326-33	2.2	70
28	Polymorphisms in the BLYS Gene Are Associated with an Increased Risk of Developing B-Cell Non-Hodgkin Lymphoma.. <i>Blood</i> , 2007 , 110, 564-564	2.2	2
27	Molecular Prognostic Factors and Outcome among a Cohort of Patients with Monoclonal B-Cell Lymphocytosis (MBL).. <i>Blood</i> , 2007 , 110, 748-748	2.2	1
26	The Prognostic Significance of Cytopenia in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL).. <i>Blood</i> , 2007 , 110, 746-746	2.2	
25	Statin Use and Risk of Non-Hodgkin Lymphoma (NHL): Preliminary Results from the Mayo Clinic Case-Control Study.. <i>Blood</i> , 2007 , 110, 2615-2615	2.2	
24	The Physician-Patient Relationship Impacts Patient Quality of Life in Chronic Lymphocytic Leukemia: Results of an International Survey of 1482 Patients.. <i>Blood</i> , 2007 , 110, 2060-2060	2.2	
23	Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. <i>Journal of Clinical Oncology</i> , 2006 , 24, 983-7	2.2	76

22	Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project. <i>Prostate</i> , 2006 , 66, 173-9	4.2	39
21	Autoimmune Cytopenias in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL): The Clinical Implications of Earlier Diagnosis and Longer Follow-Up.. <i>Blood</i> , 2006 , 108, 2789-2789	2.2	1
20	Prior Treatment Relates More Strongly to Richter Transformation Than ZAP-70, CD38, IgVH Gene Mutation Status, and Cytogenetic Abnormalities: Findings of an Observational Cohort Study of 962 Patients with CLL.. <i>Blood</i> , 2006 , 108, 2777-2777	2.2	
19	A Large Scale Evaluation of Genetic Variation in Immune and Inflammation Genes and Risk of Non-Hodgkin Lymphoma.. <i>Blood</i> , 2006 , 108, 817-817	2.2	
18	Sequence analysis of the serotonin transporter and associations with antidepressant response. <i>Biological Psychiatry</i> , 2005 , 58, 374-81	7.9	185
17	Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. <i>Neuropsychopharmacology</i> , 2004 , 29, 558-65	8.7	129
16	Genetic association studies in Alzheimer's disease research: challenges and opportunities. <i>Statistics in Medicine</i> , 2004 , 23, 169-78	2.3	19
15	Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci. <i>American Journal of Human Genetics</i> , 2004 , 75, 948-65	11	123
14	Familial Chronic Lymphocytic Leukemia(CLL): The Mayo Clinic Experience.. <i>Blood</i> , 2004 , 104, 1906-1906	2.2	
13	Genome-wide linkage analysis of systolic blood pressure: a comparison of two approaches to phenotype definition. <i>BMC Genetics</i> , 2003 , 4 Suppl 1, S13	2.6	8
12	Luteinizing hormone beta polymorphism and risk of familial and sporadic prostate cancer. <i>Prostate</i> , 2003 , 56, 30-6	4.2	17
11	Genome linkage screen for prostate cancer susceptibility loci: results from the Mayo Clinic Familial Prostate Cancer Study. <i>Prostate</i> , 2003 , 57, 335-46	4.2	46
10	No association of germline alteration of MSR1 with prostate cancer risk. <i>Nature Genetics</i> , 2003 , 35, 128-9	3.63	54
9	Mutations in CHEK2 associated with prostate cancer risk. <i>American Journal of Human Genetics</i> , 2003 , 72, 270-80	11	226
8	Evidence for a susceptibility locus for panic disorder near the catechol-O-methyltransferase gene on chromosome 22. <i>Biological Psychiatry</i> , 2002 , 51, 591-601	7.9	112
7	Analysis of the RNASEL gene in familial and sporadic prostate cancer. <i>American Journal of Human Genetics</i> , 2002 , 71, 116-23	11	97
6	Case-control studies of genetic markers: power and sample size approximations for Armitage's test for trend. <i>Human Heredity</i> , 2001 , 52, 149-53	1.1	142
5	Evaluation of candidate genes in case-control studies: a statistical method to account for related subjects. <i>American Journal of Human Genetics</i> , 2001 , 68, 1457-62	11	105

4	Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. <i>American Journal of Human Genetics</i> , 2000 , 67, 737-44	11	918
3	Patterns of dietary fluoride supplement use during infancy. <i>Journal of Public Health Dentistry</i> , 1998 , 58, 228-33	1.6	55
2	Development of smokeless tobacco-induced oral mucosal lesions. <i>Journal of Oral Pathology and Medicine</i> , 1998 , 27, 388-94	3.3	7
1	Investigating the numerical effects of ascertainment bias in linkage analysis: development of methods and preliminary results. <i>Genetic Epidemiology</i> , 1997 , 14, 1119-24	2.6	13